Intradermal Trivalent Influenza Vaccine With Imiquimod

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr Ivan FN Hung, The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT01508884
First received: January 9, 2012
Last updated: December 8, 2013
Last verified: December 2013

January 9, 2012
December 8, 2013
January 2012
December 2012   (final data collection date for primary outcome measure)
Seroconversion rate [ Time Frame: day 7 ] [ Designated as safety issue: No ]
The percentage of subjects with an hemagglutination inhibition antibody titre <10 at baseline and a post-vaccination titre of ≥40 or a titre >10 at baseline and at least a four-fold increase in titre post-vaccination on day 7
Seroconversion rate [ Time Frame: day 21 ] [ Designated as safety issue: No ]
The percentage of subjects with an hemagglutination inhibition antibody titre <10 at baseline and a post-vaccination titre of ≥40 or a titre >10 at baseline and at least a four-fold increase in titre post-vaccination on day 21
Complete list of historical versions of study NCT01508884 on ClinicalTrials.gov Archive Site
  • Geometric mean titer old increase in influenza antibody titer [ Time Frame: day 21 ] [ Designated as safety issue: No ]
    The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assays on day 21 compared to day 0
  • Seroprotection rate [ Time Frame: day 21 ] [ Designated as safety issue: No ]
    The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay on day 21
  • Adverse events (Immediate) [ Time Frame: 30 minutes after vaccination ] [ Designated as safety issue: Yes ]
    Patients who develop systemic or local adverse events within 30 minutes of vaccination
  • Geometric mean titer old increase in influenza antibody titer [ Time Frame: day 7 ] [ Designated as safety issue: No ]
    The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assay on day 7 compared to day 0
  • Seroprotection rate [ Time Frame: day 7 ] [ Designated as safety issue: No ]
    The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay on day 7
  • Geometric mean titer old increase in influenza antibody titer [ Time Frame: year 1 ] [ Designated as safety issue: No ]
    The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assay at year 1 compared to day 0
  • Seroprotection rate [ Time Frame: year 1 ] [ Designated as safety issue: No ]
    The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay at year 1
  • Seroconversion rate [ Time Frame: Year 1 ] [ Designated as safety issue: No ]
    The percentage of subjects with an hemagglutination inhibition antibody titre <10 at baseline and a post-vaccination titre of ≥40 or a titre >10 at baseline and at least a four-fold increase in titre post-vaccination at year 1
  • Adverse events (7 days) [ Time Frame: 7 days after vaccination ] [ Designated as safety issue: Yes ]
    Patients who develop systemic or local adverse events within 1 week of vaccination
  • Seroconversion rate [ Time Frame: Day 21 ] [ Designated as safety issue: No ]
    The percentage of subjects with an hemagglutination inhibition antibody titre <10 at baseline and a post-vaccination titre of ≥40 or a titre >10 at baseline and at least a four-fold increase in titre post-vaccination on day 21
  • Geometric mean titer old increase in influenza antibody titer [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
    The GMT fold increase in influenza antibody titer by hemagglutination inhibition or microneutralization antibody assay at year 1 compared to day 0
  • Seroprotection rate [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
    The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition or microneutralization antibody assay at year 1
  • Seroconversion rate [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
    The percentage of subjects with an hemagglutination inhibition antibody titre <10 at baseline and a post-vaccination titre of ≥40 or a titre >10 at baseline and at least a four-fold increase in titre post-vaccination at year 1
  • Effectiveness [ Time Frame: 1 year post vaccination ] [ Designated as safety issue: No ]
    hospitalization for pneumonia or influenza
  • Effectiveness [ Time Frame: 1 year post vaccination ] [ Designated as safety issue: No ]
    Nasopharyngeal sample positive for influenza A
  • Geometric mean titer old increase in influenza antibody titer [ Time Frame: day 21 ] [ Designated as safety issue: No ]
    The GMT fold increase in influenza antibody titer by hemagglutination inhibition antibody test on day 21 compared to day 0
  • Seroprotection rate [ Time Frame: day 21 ] [ Designated as safety issue: No ]
    The percentage of subjects achieving an antibody titer achieving an influenza antibody titer of 1:40 or above by hemagglutination inhibition antibody test on day 21
  • Adverse events [ Time Frame: 30 minutes after vaccination ] [ Designated as safety issue: Yes ]
    Patients who develop systemic or local adverse events within 30 minutes of vaccination
Not Provided
Not Provided
 
Intradermal Trivalent Influenza Vaccine With Imiquimod
Efficacy and Effectiveness of Intradermal Trivalent Influenza Vaccine With Topical Imiquimod, a Double Blind Randomized Controlled Trial

Despite the WHO International Health Regulations Emergency Committee declared an end to the 2009 H1N1 pandemic globally, the emergence of the novel 2009 H1N1 virus in March 2009 has affected more than 214 countries with at least 18000 deaths [1]. Patients with chronic underlying illness and extreme of ages are at risk of developing severe disease and complications [2-3]. Resistance to oseltamivir has also been reported [4]. Therefore, vaccination with the 2010/2011 trivalent influenza vaccine (TIV) with the 2009 H1N1-like virus incorporated will be the best protection against the influenza infection, especially among the at risk population. Recent study on dose sparing seasonal influenza vaccine delivered via a novel intradermal microneedle has demonstrated good immunogenic responses similar to full-dose intramuscular vaccination [6]. Poor immunogenicity of the H1N1 2009 component of the trivalent influenza has been reported [7].

Study has also suggested the combined intradermal vaccination with local stimulation of dermal antigen presenting cells by applying imiquimod cream (Aldara) to the injection site, which activate antigen presenting cells (APC) through the toll-like receptor 7 (TLR7) may produce better immunogenicity [8].

Imiquimod cream is currently registered for the treatment of warts and basal cell carcinoma. Scientific evidence has demonstrated that after treatment with imiquimod, the antigen is processed and presented to cells of the adaptive immune system leading to clearance of the virus and subsequent clearance of the lesions [9]. In addition to functional maturation, imiquimod induces migration of dendritic cells from the dermis to draining lymph nodes [10,11]. Subcutaneous administration of imiquimod as vaccine adjuvant simultaneously with the antigen of interest, has shown to induce enhanced responses towards the administered antigen [12].

We therefore performed a prospective, double blind, randomized controlled study to compare the safety and immunogenicity between intradermal 2011/2012 TIV immunization with pretreatment of imiquimod cream and conventional full dose intramuscular 2011/2012 TIV immunization with pretreatment of aqueous cream as control.

References

  1. World Health Organization. Influenza A (H1N1) - update 95 [cited 2010 April 10]. Available from http://www.who.int/csr/don/2009_12_30/en/index.html
  2. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374: 2072-9.
  3. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302: 1896-902.
  4. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.
  5. Chen H, Cheung CL, Tai H, et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis 2009;15:1970-2.
  6. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009;27:454-9
  7. Myers CA, Faix DJ, Blair PJ. Possible reduced effectiveness of the 2009 H1N1 component of live, attenuated influenza vaccine. Clin Infect Dis. 2011;15;53:207-8.9.
  8. Roukens R, Vossen AC, Boland GJ, et al. Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara). Vaccine 2010;4288-4293.
  9. Tyring S, Conant M, Marini M, Van Der Meijden W, Washenik K. Imiquimod, an international update on therapeutic uses in dermatology. Int J Dermatol 2002;41(11):810-6.
  10. Burns Jr RP, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000;94(1):13-23.
  11. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114(1):135-41.
  12. Thomsen LL, Topley P, Daly MG, Brett SJ, Tite JP. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 2004;22(13-14):1799-809.
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Chronic Illness
  • Biological: influenza vaccine
    single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
    Other Name: Intanza 15
  • Drug: Imiquimod
    pretreatment with topical imiquimod cream to the injection site before vaccination
    Other Name: Aldara
  • Biological: influenza vaccine
    single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
    Other Name: Intanza 15
  • Drug: Aqueous cream
    pretreatment with topical aqueous cream to the injection site before vaccination
  • Biological: influenza vaccine
    single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
    Other Name: Vaxigrip
  • Active Comparator: IM vaccine and placebo cream
    A single dose of intramuscular influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
    Interventions:
    • Biological: influenza vaccine
    • Drug: Aqueous cream
  • Active Comparator: ID vaccine and placebo cream
    A single dose of intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
    Interventions:
    • Biological: influenza vaccine
    • Drug: Aqueous cream
  • Experimental: ID vaccine and imiquimod cream
    A single dose intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with imiquimod cream applied to the skin before vaccination
    Interventions:
    • Biological: influenza vaccine
    • Drug: Imiquimod
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
93
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All adult patients at the age of 21 or above with chronic illness and given written informed consent
  • Subjects must be available to complete the study and comply with study procedures. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.

Exclusion Criteria:

  • Clinically significant immune-related diseases or significant recent co-morbidities
  • Inability to comprehend and to follow all required study procedures
  • History or any illness that might interfere with the results of the study or pose additional risk to the subjects due to participation in the study
  • Have received 2011/2012 TIV
  • Have a recent history (documented, confirmed or suspected) of a flu-like disease within a week of vaccination.
  • Have a known allergy to eggs or other components of the Study Vaccines (including gelatin, formaldehyde, octoxinol, thimerosal, and chicken protein), or history of any anaphylaxis, serious vaccine reactions, to any excipients.
  • Have a positive urine or serum pregnancy test within 24 hours prior to vaccination, or women who are breastfeeding.
  • Female of childbearing potential, not using any acceptable contraceptive methods for at least 2 months prior to study entry or that do not plan to use acceptable birth control measures during the first 3 weeks after vaccination.
  • Have immunosuppression as a result of an underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months.
  • Have an active neoplastic disease or a history of any hematologic malignancy.
  • Have long-term use of glucocorticoids including oral, parenteral or high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months. (Nasal and topical steroids are allowed).
  • Have a history of receiving immunoglobulin or other blood product within the 3 months prior to vaccination in this study.
  • Have known active human immunodeficiency virus (HIV) infection, acute hepatitis B or C infection, autoimmune hepatitis and related cirrhosis
  • Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study or expect to receive an experimental agent during this study. Unwilling to refuse participation in another clinical study through the end of this study.
  • History of progressive or severe neurological disorders
  • Have received any licensed vaccines within 4 weeks or inactivated licensed vaccines within 2 weeks prior to vaccination in this study or plan receipt of such vaccines within 21 days following the second vaccination (only exception being unadjuvanted seasonal influenza vaccines which are allowed until 1 week prior to and after 1 week study vaccinations).
  • Axillary temperature ≥ 38°C or oral temperature ≥ 38.5°C within 3 days of intended study vaccination
  • Surgery planned during the study period that in the Investigator's opinion would interfere with the study visits schedule
  • Have a history of alcohol or drug abuse in the last 5 years.
  • Have a history of Guillain-Barré Syndrome.
  • Have any condition that the investigator believes may interfere with successful completion of the study.
Both
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Hong Kong
 
NCT01508884
HKU-2012-432
No
Dr Ivan FN Hung, The University of Hong Kong
The University of Hong Kong
Not Provided
Principal Investigator: Ivan FN Hung, MD FRCP The University of Hong Kong
The University of Hong Kong
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP